Perampanel: A Significant Liver Enzyme Inducer in Some Patients?

被引：6

作者：

Novy, Jan ^{[1
]}

Rothuizen, Laura E. ^{[2
,3
]}

Buclin, Thierry ^{[2
,3
]}

Rossett, Andrea O. ^{[1
]}

机构：

[1] CHU Vaudois, Dept Clin Neurosci, CH-1011 Lausanne, Switzerland

[2] CHU Vaudois, Div Clin Pharmacol, CH-1011 Lausanne, Switzerland

[3] Univ Lausanne, Lausanne, Switzerland

来源：

EUROPEAN NEUROLOGY | 2014年 / 72卷 / 3-4期

关键词：

Anti-epileptic drug; Serum levels monitoring; Pharmacokinetic interaction; PHASE-III; ADJUNCTIVE PERAMPANEL; PHENYTOIN;

D O I：

10.1159/000362446

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Perampanel is one of the latest released antiepileptic drugs (AEDs). Early studies suggest no significant liver enzyme induction from this compound. We report on two patients with medically resistant epilepsy, who had perampanel added to their usual regimen. Both experienced a worsening of their epilepsy and presented in convulsive status epilepticus; concurrent antiepileptic drug levels (phenytoin, phenobarbital, rufinamide) were significantly decreased (<50%) in comparison with levels prior to perampanel introduction. Intravenous load and significant increase of maintenance dosages were needed to restore therapeutic drug levels. In one patient, further increase of perampanel resulted in a new drop of phenytoin level. This suggests that perampanel could, in some subjects, induce liver enzymes and interact with concomitant AEDs; monitoring levels of concomitant compounds could be useful. (C) 2014 S. Karger AG, Basel

引用

页码：213 / 216

页数：4

共 10 条

[1]

Bajpai M, 1996, DRUG METAB DISPOS, V24, P1401

[2]

Biton V, 2009, TREATMENT EPILEPSY, P647

[3] Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305 [J].

French, Jacqueline A. ;

Krauss, Gregory L. ;

Steinhoff, Bernhard J. ;

Squillacote, David ;

Yang, Haichen ;

Kumar, Dinesh ;

Laurenza, Antonio .

EPILEPSIA, 2013, 54 (01) :117-125

[4] Adjunctive perampanel for refractory partial-onset seizures Randomized phase III study 304 [J].

French, Jacqueline A. ;

Krauss, Gregory L. ;

Biton, Victor ;

Squillacote, David ;

Yang, Haichen ;

Laurenza, Antonio ;

Kumar, Dinesh ;

Rogawski, Michael A. .

NEUROLOGY, 2012, 79 (06) :589-596

[5]

Krauss GL, 2008, 62 ANN M AM EP SOC 2

[6] Perampanel, a selective, noncompetitive ℵ-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: Interim results from phase III, extension study 307 [J].

Krauss, Gregory L. ;

Perucca, Emilio ;

Ben-Menachem, Elinor ;

Kwan, Patrick ;

Shih, Jerry J. ;

Squillacote, David ;

Yang, Haichen ;

Gee, Michelle ;

Zhu, Jin ;

Laurenza, Antonio .

EPILEPSIA, 2013, 54 (01) :126-134

[7]

Laurenza A, 2011, EPILEPSY CURRENTS, V11

[8]

Michelucci R., 2009, TREATMENT EPILEPSY, P585

[9] PHARMACOKINETIC DRUG-INTERACTIONS WITH PHENYTOIN .1. [J].

NATION, RL ;

EVANS, AM ;

MILNE, RW .

CLINICAL PHARMACOKINETICS, 1990, 18 (01) :37-60

[10]

Patsalos PN, 2013, CLIN PHARMA IN PRESS

← 1 →